Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.30 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31234416 | 1.00 | PTPN1 (0.34) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL2494729 | 1.00 | PTPN1 (0.34) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL18204848 | 1.00 | PTPN1 (0.34) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL2494727 | 1.00 | PTPN1 (0.34) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL12192438 | 1.00 | PTPN1 (0.34) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL15122945 | 1.00 | PTPN1 (0.34) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL15133204 | 0.89 | CHRM2 (0.32) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL20380929 | 0.87 | GLA (0.34) | NR1H2 | |
| SCHEMBL18612437 | 0.87 | GLA (0.34) | NR1H2 | |
| SCHEMBL5455578 | 0.86 | MAPT (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010234-A1 | PROCESS FOR MANUFACTURING A GLUTAMIC ACID DERIVATIVE AND A PYROGLUTAMIC ACID DERIVATIVE AND A NOVEL INTERMEDIATE IN THE MANUFACTURE THEREOF | AJINOMOTO CO. INC (JP) | 2010-01-14 | — | — | US | claimed |
| US-20060009394-A1 | Process for manufacturing a glutamic acid derivative and a pyroglutamic acid derivative and a novel intermediate in the manufacture thereof | AJINOMOTO CO. INC (JP) | 2006-01-12 | — | — | US | claimed |
| US-8394970-B2 | Process for manufacturing a glutamic acid derivative and a pyroglutamic acid derivative and a novel intermediate in the manufacture thereof | AJINOMOTO CO., INC. (JP) | 2013-03-12 | — | — | US | disclosed |
| EP-1582514-B1 | PROCESSES FOR PRODUCING GLUTAMIC ACID DERIVATIVE, A PYROGLUTAMIC ACID DERIVATIVE AND A NOVEL INTERMEDIATE FOR PRODUCTION | AJINOMOTO KK (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-7674915-B2 | Process for manufacturing a glutamic acid derivative and a pyroglutamic acid derivative and a novel intermediate in the manufacture thereof | AJINOMOTO CO., INC. (JP) | 2010-03-09 | — | — | US | disclosed |
| US-20100010234-A1 | PROCESS FOR MANUFACTURING A GLUTAMIC ACID DERIVATIVE AND A PYROGLUTAMIC ACID DERIVATIVE AND A NOVEL INTERMEDIATE IN THE MANUFACTURE THEREOF | AJINOMOTO CO. INC (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20060009394-A1 | Process for manufacturing a glutamic acid derivative and a pyroglutamic acid derivative and a novel intermediate in the manufacture thereof | AJINOMOTO CO. INC (JP) | 2006-01-12 | — | — | US | disclosed |
| EP-1582514-A1 | PROCESSES FOR PRODUCING GLUTAMIC ACID DERIVATIVE AND PYROGLUTAMIC ACID DERIVATIVE AND NOVEL INTERMEDIATE FOR PRODUCTION | Ajinomoto Co., Inc. (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010234-A1 | PROCESS FOR MANUFACTURING A GLUTAMIC ACID DERIVATIVE AND A PYROGLUTAMIC ACID DERIVATIVE AND A NOVEL INTERMEDIATE IN THE MANUFACTURE THEREOF | PTMA, GRIK5, GLUL | PTPN1 4780/4885NR1H2 4627/4885NR1H3 4593/4885 |
| US-20060009394-A1 | Process for manufacturing a glutamic acid derivative and a pyroglutamic acid derivative and a novel intermediate in the manufacture thereof | PTMA, GRIK5, GLUL | PTPN1 4780/4885NR1H2 4627/4885NR1H3 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.